What Bryan Johnson's Stomach Teaches Us About Longevity Medicine

Bryan Johnson's missed autoimmune gastritis diagnosis reveals why more data isn't enough, interpretation matters. Lessons for longevity medicine.

Bryan Johnson has spent a reported two million dollars a year tracking almost every measurable feature of his own biology. He is fit, he sleeps more than eight hours a night, and he claims a fertility age in his early twenties. He is 48. Last week he announced that he has a chronic autoimmune disease called autoimmune gastritis. In his own words, his stomach is eating itself.

The headlines have leaned into the irony. Eleven years of flagged bloodwork, the most obsessive self tracking protocol on the planet, and a slow disease still hid in plain sight for a decade. That is a fair observation. It is also the wrong lesson to walk away with. The more useful question is why the miss happened, what it says about the difference between measuring a body and understanding one, and what any of this means for the growing field of longevity medicine. Let us work through it properly.

What autoimmune gastritis actually is

Your stomach lining contains specialised cells called parietal cells. They do two important jobs. They make the acid you need to digest food, and they secrete a protein called intrinsic factor, which lets you absorb vitamin B12 in the small intestine.

In autoimmune gastritis the immune system produces antibodies that attack these parietal cells. Over time the acid producing part of the stomach lining thins out and atrophies. Two things follow. Acid production falls, and B12 absorption fails. Iron absorption suffers as well, because stomach acid helps you take up dietary iron. The result is often iron deficiency first, then B12 deficiency and a specific type of anaemia called pernicious anaemia, and in some cases nerve damage from prolonged B12 loss.

The condition is quiet. It commonly develops over years to decades with no clear symptoms, which is exactly why it evades detection. The earliest clue is often a low ferritin, the marker of stored iron, long before anaemia appears. That is the signal Johnson says was repeatedly dismissed. His haemoglobin looked normal because the body drains its iron reserves first to keep circulating iron up. You can be genuinely iron deficient with a normal haemoglobin. His diagnosis was confirmed the way it should be, with a gastroscopy, biopsies from several regions of the stomach, and blood tests showing anti parietal cell antibodies about five times the upper limit of normal.

There is a longer term reason to take it seriously. Autoimmune gastritis carries an increased risk of certain gastric tumours, including type 1 gastric neuroendocrine tumours and, over time, gastric cancer. Early identification and surveillance matter.

How common is it

More common than most people assume, and almost certainly underdiagnosed.

Global prevalence estimates vary depending on how you define and detect the condition. Older serology based figures put it somewhere between 0.3 and 2.7 percent of the general population. More recent pooled analyses and reviews land closer to 3.8 percent worldwide. Johnson himself quoted a range of 2 to 5 percent, which sits comfortably inside that spread.

The variation is not sloppiness. It reflects a real problem. The disease is silent, the diagnostic criteria are not fully standardised, and antibody positivity is far more common than confirmed disease. One recent Chinese hospital study found anti parietal cell antibodies in 12.6 percent of people tested, while confirmed autoimmune gastritis sat at 3.9 percent. That gap between antibody positive and clinically diagnosed is the whole story of this condition. Most of it is hiding.

We do not have a clean Australia specific prevalence figure for autoimmune gastritis on its own, and I will not invent one. What we can say is that autoimmune disease as a category affects around 5 percent of Australians, per the Australian Institute of Health and Welfare and ASCIA, the peak immunology body here. Given the global figures above, it is reasonable to assume tens of thousands of Australians carry autoimmune gastritis, many of them undiagnosed, and many of them sitting in general practice waiting rooms with an unexplained low ferritin that keeps getting topped up rather than investigated.

Autoimmune disease as a whole

Autoimmune gastritis belongs to a family of more than 80 to 100 related conditions in which the immune system mistakes the body's own tissues for a threat. Together they affect roughly 4.5 to 5 percent of people globally and around 5 percent of Australians, which makes them collectively more common than either cancer or heart disease. They are chronic, mostly lifelong, and they range from very common to very rare.

There is a strong sex skew. Women carry most of the burden. The often quoted figure is that 80 percent of autoimmune diagnoses occur in women. More recent and broader analysis puts it closer to two thirds, still a large imbalance. The reasons are complex and involve sex hormones, X chromosome biology, and immune response differences.

The conditions people are most likely to encounter, and where they cluster by sex, look roughly like this.

More common in women:
- Autoimmune thyroid disease, including Hashimoto thyroiditis and Graves disease. This is the most common group of all and the one most often linked to autoimmune gastritis.
- Systemic lupus erythematosus, which has one of the strongest female skews of any autoimmune disease.
- Rheumatoid arthritis.
- Multiple sclerosis.
- Sjogren disease.
- Coeliac disease.

Roughly equal, or more common in men:
- Type 1 diabetes, which occurs at close to equal rates in males and females, perhaps with a slight male lean.
- Ankylosing spondylitis and related spondyloarthritis.
- Primary biliary cholangitis and autoimmune myocarditis, both of which are actually more common in men.

One theme runs through all of this and is central to Johnson's case. Autoimmune conditions travel in packs. His diagnosis was not one problem but three linked together: iron deficiency, the autoimmune gastritis driving it, and autoimmune thyroid disease alongside it. This clustering has a name, thyrogastric syndrome, and it is well documented. Hashimoto thyroiditis is several fold more common in people with autoimmune gastritis than in the general population. If you have one organ specific autoimmune disease, the odds of a second one go up. That is not fringe medicine. That is standard clinical reasoning, and it is the reasoning that should have connected a persistently low ferritin to a known thyroid condition years earlier.

Now to the longevity arm

Here is where the story gets interesting for our field, and where the honest account matters more than the hot take.

Some of what Johnson does is genuinely out on the edge and not appropriate for most people. Swapping blood with a family member, tracking overnight erections as a biomarker, a near total avoidance of sunlight, and an intervention list that runs to dozens of compounds a day. Set aside whether any single item works. The bigger issue is access and cost. A protocol that consumes seven figures a year and a personal team of doctors is not a public health strategy. It is a single very wealthy person running an experiment on himself. Presenting that as a template for the general population would be dishonest, and it is fair to say so plainly.

But it would be equally dishonest to dismiss the whole enterprise. Some of what sits in the longevity space has real mechanistic credibility. There are pathways in ageing biology, senescent cell clearance, metabolic and mTOR signalling, mitochondrial function, chronic low grade inflammation, that are well supported at the level of cell and animal biology. The problem is not the mechanism. The problem is the leap from mechanism to outcome in real humans. A compound can do exactly what the biology predicts in a dish and still fail to change anything that matters when you give it to a person, or worse, cause harm that only shows up at scale. Mechanistic plausibility is a reason to investigate. It is not proof of benefit. Those are two different claims, and most of the hype in this space comes from collapsing the second into the first.

So the honest position is a middle one. Some longevity practices are unproven and should be called unproven. Some are plausible and being tested, and should be described as promising but not yet established. And a large amount of what actually moves the needle on how long and how well people live is not exotic at all. It is sleep, muscle, cardiovascular fitness, nutrition, not smoking, managing blood pressure and glucose, and catching the treatable things early. Johnson's own case is the perfect illustration. The frontier immune therapies he is now exploring for his gastritis, the JAK inhibitors and CAR-T style approaches, are genuinely investigational, some not yet built. Meanwhile the thing that would have helped him most was boring and cheap. Investigate a low ferritin instead of waving it through.

There is a real irony worth naming. The most measured man alive was let down not by a lack of advanced technology but by a failure of basic clinical follow through on a common, cheap marker. More data did not save him. Better interpretation would have.

Why this is the frontier of the future

Step back and the case for longevity medicine becomes a case about a gap, and the gap is between lifespan and healthspan.

We are living longer than any generation before us. We are not necessarily living better. The extra years are too often years of disability, chronic disease, and dependence rather than years of vitality. Lifespan has pulled ahead of healthspan, and closing that gap is the actual goal. This is the idea of compression of morbidity, first described by James Fries at Stanford in 1980. The aim is not to add more years to your life. It is to get more life out of your years, so that the period of decline at the end is as short as possible rather than as long as possible.

If the human argument does not persuade, the economic one should. An ageing population with a widening lifespan to healthspan gap is a slow moving fiscal problem. Every additional year a person spends disabled, hospitalised, or dependent is a cost carried by health budgets, aged care, lost productivity, and families. Every additional disability free year does the opposite. It keeps people working, independent, and out of the acute system. This is why governments and health systems around the world are starting to invest seriously in longevity and preventive medicine. It is not indulgence. On the health economics alone it is one of the highest leverage investments a health system can make. Prevention and early detection are cheaper than late stage disease by an enormous margin, and the demographic maths is only moving one way.

That is the frontier. Not immortality, and not two million dollar protocols. A serious, evidence governed effort to extend the healthy, functional, disability free portion of people's lives, at a cost that scales beyond the very wealthy.

What we do at AvaElis, and why it is different

This is exactly the space AvaElis was built for, and the Johnson story maps almost perfectly onto how we think a longevity practice should operate.

We start cheap and fundamental. The highest value work is usually not the newest or the most expensive. It is thorough, well interpreted baseline diagnostics and acting on what they show. A persistent low ferritin gets investigated, not just topped up. A known thyroid condition prompts a look at what tends to travel with it. That is unglamorous and it is where most of the real gains sit.

We explore advanced diagnostics where they add genuine value, not for their own sake. More data is only useful if someone interprets it correctly and acts on it. Johnson's decade long miss is the cautionary tale. The measurement was never the problem. The interpretation was.

And we are honest about the evidence tier of everything we offer. Where something is well established, we say so and we ground it in the fundamentals first. Where something is emerging, mechanistically plausible but not yet proven in real outcomes, we call it exactly that and we walk you through the pros and cons before you decide. We do not dress up the speculative as settled, and we do not dismiss the promising as worthless. We tell you which is which.

That is the point of difference. Not the longest supplement list or the flashiest device. A practice that separates the science from the hype, starts with the cheap and proven, is transparent about the rest, and keeps the actual goal in view. More healthy years, explained honestly, and available to more than just the people who can spend millions trying to live forever.

---

General information, not individual medical advice. Speak to your own doctor.